A Study of AK106-001616 in Patients With Rheumatoid Arthritis (RA)

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

To investigate the efficacy and safety of AK106-001616 in patients with rheumatoid arthritis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asahi Kasei Pharma Corporation

Criteria

Inclusion Criteria:

• Diagnosis of RA (class I to III)

• Stable dose of methotrexate (at least 12 weeks)

Exclusion Criteria:

• Pregnant or breastfeeding

• Abnormal screening laboratory test values considered to be clinically significant